Delivery Order SPE2DB22D3004-SPE2DB25FSB34
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,336.32 to AmerisourceBergen Drug Corp for Loestrin 21 1.5-30 tablets (21-tablet supply) on July 31, 2025, with ultimate completion by August 1, 2025. This is a firm fixed price, non-set-aside delivery order supporting federal pharmaceutical procurement requirements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled the order from its corporate office location in...
- The Defense Logistics Agency awarded a $3,121.57 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Loestrin 21 1.5-30 tablets (21-count packages). This is a firm fixed price delivery order with no set-aside designation, representing a competitively awarded contract. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This award is...
- The Defense Logistics Agency awarded a delivery order valued at $2,838.58 to AmerisourceBergen Drug Corp for Loestrin 21 1-20 Tablet (21-count packages) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive award, which received no set-aside designation, represents a firm fixed-price delivery order to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract is a child award issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $14,675.22 to AmerisourceBergen Drug Corp for the supply of Loestrin FE 1-20 tablets in 28-count packages. The contract is firm fixed price with no set-aside designation and carries an ultimate completion date of July 30, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical delivery. This delivery order represents a child contract under...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Loestrin 21 1-20 tablets (21-count packages) under a firm fixed-price contract with a ceiling value of $3,580.26. This non-competitive delivery order is expected to be completed by August 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of Loestrin 21 1-20 tablet 21s, a pharmaceutical product. The contract has a ceiling value of $5,604.02 and a period of performance through April 9, 2024. AmerisourceBergen Drug Corp serves as the prime contractor on this order, which is part of a larger indefinite delivery contract (IDC) awarded by DLA...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $1,123.02 contract is for the supply of Loestrin 21 1-20 tablet 21s, with an ultimate completion date of April 5, 2024. This delivery order is part of a broader indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, valued up to $999,999,999.00 through...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical distribution company. The $3,422.36 contract is for the supply of 4564205610 LOESTRIN 21 1.5-30 TABLET 21S, a pharmaceutical product, with an ultimate completion date of April 9, 2024. Amerisourcebergen Drug Corp is also the prime contractor on an indefinite delivery contract (IDC) with DLA,...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract worth $3,115.38 to provide Loestrin 21 1-20 tablets. This order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, valued up to $999,999,999.00 through December 31, 2025, to deliver a comprehensive range of pharmaceutical products and medical supplies to support...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for Loestrin 21 1-20 Tablet in quantities of 21 tablets, with a contract ceiling value of $2,983.50 and a firm fixed price structure. The contract is non-set-aside and represents a competitive award for pharmaceutical supply. This delivery order is completed by July 31, 2025, and will be performed at the contractor's corporate office location in Conshohocken,...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSB34Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,816.41 to AmerisourceBergen Drug Corp for the supply of Loestrin 21 1.5-30 tablets (21-count package). The contract, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, is a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp has demonstrated significant capability in federal medical procurement through its extensive portfolio of competitively awarded contracts with DLA, consistently delivering both brand-name and generic medications across multiple therapeutic domains. The company's role as a primary pharmaceutical vendor supports critical federal healthcare systems, including the Defense Health Agency, U.S. Coast Guard, and other government medical supply chains, positioning it as a strategic supplier for military and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/19/25 |